|
|
TTD Drug ID:
DAP000913
Drug
Information |
Name | Masoprocol | Synonyms | 741285-10-9; meso-NDGA; NCGC00094201-01; NDGA; C18H22O4; EU-0100877; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol; AC1Q7ACC; AC1L2G35; 27686-84-6; DB00179; (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 334707-72-1; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; meso-4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol; 1,2-Benzenediol, 4,4'-((2R,3S)-2,3-dimethyl-1,4-butanediyl)bis-, rel-; EINECS 248-606-6; D04862; CHX-100; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; Masoprocol (USAN/INN); NCGC00094201-04; ZINC00012342; CID71398; Nordihydroguaiaretic acid (meso-form); ZINC12359927; Actinex (TN); Lopac0_000877; Lopac-N-5023; C10719; 500-38-9; BIDD:ER0127; Masoprocolum [INN-Latin]; NCGC00015741-03; NCGC00094201-02; TNP00263; Actinex; UNII-7BO8G1BYQU; CHX 100; NCGC00015741-02; Masoprocolum; meso-Nordihydroguaiaretic acid; meso-4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol; Nordihydroguaiaretic acid from Larrea divaricata (creosote bush); LS-174190; Masoprocol; CHEMBL313972; Masoprocol [USAN:INN]; N 5023; NCGC00015741-01 | Indication | Prostate cancer [ICD9: 185 ICD10: C61] | Approved [1] | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
| InChI | 1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)1 8(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+ | InChIKey | HCZKYJDFEPMADG-TXEJJXNPSA-N | Canonical SMILES | CC(CC1=CC(=C(C=C1)O)O)C(C)CC2=CC(=C(C=C2)O)O | Isomeric SMILES | C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O | Therapeutic Class | Antineoplastic Agents | CAS Number | CAS 500-38-9 | Formula | C18H22O4 | PubChem Compound ID | CID 71398. | PubChem Substance ID | SID 12902. | SuperDrug ATC ID | L01XX10 | SuperDrug CAS ID | 027686846; | Target | Arachidonate 5-lipoxygenase |  | Inhibitor | [2] | Ref 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference | Ref 2 | Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL. Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E593-600. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|